| Code | CSB-RA024093MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to the reference antibody described in US11008399B2, targeting TPBG (trophoblast glycoprotein, also known as 5T4 or WAIF1). TPBG is a leucine-rich repeat glycoprotein that is normally expressed at low levels in most adult tissues but becomes significantly upregulated in various malignancies. This oncofetal antigen plays important roles in cellular processes including epithelial-mesenchymal transition, cancer cell migration, and metastasis. TPBG overexpression has been documented in numerous cancers including colorectal, gastric, ovarian, and renal cell carcinomas, where its expression often correlates with poor prognosis and increased metastatic potential.
The reference antibody patent describes therapeutic applications targeting TPBG-expressing cancer cells, making this biosimilar particularly valuable for oncology research. This antibody serves as an essential tool for investigating TPBG expression patterns in tumor samples, studying cancer stem cell biology, exploring mechanisms of tumor progression and metastasis, and evaluating TPBG as a therapeutic target in preclinical models.
There are currently no reviews for this product.